186 related articles for article (PubMed ID: 10645758)
1. Medical costs of managed care in patients with type 2 diabetes mellitus.
Bhattacharyya SK; Else BA
Clin Ther; 1999 Dec; 21(12):2131-42. PubMed ID: 10645758
[TBL] [Abstract][Full Text] [Related]
2. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus.
Menzin J; Korn JR; Cohen J; Lobo F; Zhang B; Friedman M; Neumann PJ
J Manag Care Pharm; 2010 May; 16(4):264-75. PubMed ID: 20433217
[TBL] [Abstract][Full Text] [Related]
3. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research.
Pelletier EM; Smith PJ; Boye KS; Misurski DA; Tunis SL; Minshall ME
Appl Health Econ Health Policy; 2008; 6(2-3):103-12. PubMed ID: 19231904
[TBL] [Abstract][Full Text] [Related]
4. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
5. Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective.
Laliberté F; Bookhart BK; Vekeman F; Corral M; Duh MS; Bailey RA; Piech CT; Lefebvre P
J Manag Care Pharm; 2009 May; 15(4):312-22. PubMed ID: 19422271
[TBL] [Abstract][Full Text] [Related]
6. Total and component health care costs in a non-Medicare HMO population of patients with and without type 2 diabetes and with and without macrovascular disease.
Gandra SR; Lawrence LW; Parasuraman BM; Darin RM; Sherman JJ; Wall JL
J Manag Care Pharm; 2006 Sep; 12(7):546-54. PubMed ID: 16981800
[TBL] [Abstract][Full Text] [Related]
7. Incremental cardiovascular costs and resource use associated with diabetes: an assessment of 29,863 patients in the US managed-care setting.
Straka RJ; Liu LZ; Girase PS; DeLorenzo A; Chapman RH
Cardiovasc Diabetol; 2009 Sep; 8():53. PubMed ID: 19781099
[TBL] [Abstract][Full Text] [Related]
8. Medical claim cost impact of improved diabetes control for medicare and commercially insured patients with type 2 diabetes.
Fitch K; Pyenson BS; Iwasaki K
J Manag Care Pharm; 2013 Oct; 19(8):609-20, 620a-620d. PubMed ID: 24074007
[TBL] [Abstract][Full Text] [Related]
9. Relationship of glycemic control to total diabetes-related costs for managed care health plan members with type 2 diabetes.
Shetty S; Secnik K; Oglesby AK
J Manag Care Pharm; 2005 Sep; 11(7):559-64. PubMed ID: 16137213
[TBL] [Abstract][Full Text] [Related]
10. Impact of initiating insulin glargine disposable pen versus vial/syringe on real-world glycemic outcomes and persistence among patients with type 2 diabetes mellitus in a large managed care plan: a claims database analysis.
Xie L; Zhou S; Pinsky BW; Buysman EK; Baser O
Diabetes Technol Ther; 2014 Sep; 16(9):567-75. PubMed ID: 24735083
[TBL] [Abstract][Full Text] [Related]
11. Empiric investigation on direct costs-of-illness and healthcare utilization of Medicaid patients with diabetes mellitus.
Guo JJ; Gibson JT; Gropper DM; Oswald SL; Barker KN
Am J Manag Care; 1998 Oct; 4(10):1433-46. PubMed ID: 10338736
[TBL] [Abstract][Full Text] [Related]
12. Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis.
Pelletier EM; Shim B; Ben-Joseph R; Caro JJ
Pharmacoeconomics; 2009; 27(6):479-90. PubMed ID: 19640011
[TBL] [Abstract][Full Text] [Related]
13. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study.
Balkrishnan R; Rajagopalan R; Camacho FT; Huston SA; Murray FT; Anderson RT
Clin Ther; 2003 Nov; 25(11):2958-71. PubMed ID: 14693318
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the relationship between a chronic disease care management program and california pay-for-performance diabetes care cholesterol measures in one medical group.
Cutler TW; Palmieri J; Khalsa M; Stebbins M
J Manag Care Pharm; 2007 Sep; 13(7):578-88. PubMed ID: 17874864
[TBL] [Abstract][Full Text] [Related]
15. Resource utilization and costs associated with using insulin therapy within a newly diagnosed type 2 diabetes mellitus population.
Bell K; Parasuraman S; Raju A; Shah M; Graham J; Denno M
J Manag Care Spec Pharm; 2015 Mar; 21(3):220-8a. PubMed ID: 25726031
[TBL] [Abstract][Full Text] [Related]
16. Economic burden of rhinitis in managed care: a retrospective claims data analysis.
Dalal AA; Stanford R; Henry H; Borah B
Ann Allergy Asthma Immunol; 2008 Jul; 101(1):23-9. PubMed ID: 18681080
[TBL] [Abstract][Full Text] [Related]
17. Patterns of expenditures and use of services among older adults with diabetes. Implications for the transition to capitated managed care.
Krop JS; Powe NR; Weller WE; Shaffer TJ; Saudek CD; Anderson GF
Diabetes Care; 1998 May; 21(5):747-52. PubMed ID: 9589235
[TBL] [Abstract][Full Text] [Related]
18. Healthcare costs associated with depression in medically Ill fee-for-service medicare participants.
Unützer J; Schoenbaum M; Katon WJ; Fan MY; Pincus HA; Hogan D; Taylor J
J Am Geriatr Soc; 2009 Mar; 57(3):506-10. PubMed ID: 19175438
[TBL] [Abstract][Full Text] [Related]
19. What Contributes Most to High Health Care Costs? Health Care Spending in High Resource Patients.
Pritchard D; Petrilla A; Hallinan S; Taylor DH; Schabert VF; Dubois RW
J Manag Care Spec Pharm; 2016 Feb; 22(2):102-9. PubMed ID: 27015249
[TBL] [Abstract][Full Text] [Related]
20. Comorbidities, healthcare service utilization and costs for patients identified with painful DPN in a managed-care setting.
Ritzwoller DP; Ellis JL; Korner EJ; Hartsfield CL; Sadosky A
Curr Med Res Opin; 2009 Jun; 25(6):1319-28. PubMed ID: 19419344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
